Accumulated Losses of RMB 4.8 Billion — Why Do Investors Value Blue Arrow Aerospace at RMB 75 Billion?
Bleeding cash, tiny revenue, huge valuation
Blue Arrow Aerospace (蓝箭航天) posted RMB 36.43 million revenue in H1 2025 and a H1 loss of RMB 597 million. From 2022 through mid‑2025 the company’s accumulated operating losses exceed RMB 4.8 billion, with only RMB 721 million cash on the balance sheet and a burn rate of just over RMB 100 million a month. Yet the firm has applied for a STAR Market (科创板) IPO to raise RMB 7.5 billion — an offering that, if no less than 10% of total shares are sold, implies a post‑IPO valuation of RMB 75 billion. If you run a factory, these numbers look absurd. If you’re an investor, you ask: what future is priced in?
The valuation anchor: launch capability and a massive demand story
The market’s faith is straightforward and stark: rocket launch services. Blue Arrow’s Zhuque‑3 (朱雀三号) is designed to be reusable and to cut per‑kg launch costs; its first flight achieved second‑stage orbital insertion in December 2025 while the first‑stage recovery failed. In H1 2025 launch services accounted for 97.97% of Blue Arrow’s revenue — and nearly all of that revenue came from a single customer. Customer concentration of 98% is an existential commercial risk: one sneeze from that customer and revenue collapses.
Why tolerate that concentration? Investors are underwriting the addressable market. China has public plans for more than 60,000 satellites while only a tiny fraction are currently in orbit. The comparison to SpaceX is instructive: SpaceX (SpaceX) monetized launch capability into Starlink — a recurring revenue platform that dwarfs pure launch receipts. Blue Arrow’s pitch is similar in logic: absorb huge R&D and cash burn now, prove reusability, then compete on scale and cost as constellation deployment accelerates. That future is distant and capital intensive. The valuation, therefore, prices optionality on scale — if the market grows and Blue Arrow drives cost down, upside is large; if not, downside is painful.
Financing, policy window and sector implications
Blue Arrow’s funding history shows why public markets matter. Early angel bets financed the first rocket; later rounds — including large injections from state‑linked funds such as Yizhuang Industrial Fund (亦庄产业基金), Wuxi Industrial Development (无锡产发), the National Industrial Investment Fund (国家产业投资基金) and the National Manufacturing Transformation Fund (国家制造业转型基金) — transformed the cap table. It has been reported that several early private investors exited ahead of IPO as fund life‑cycles matured. The company’s prospectus also shows cumulative negative operating cash flow of about RMB 3.3 billion from 2022 to H1 2025, meaning the IPO proceeds are largely survival capital: RMB 2.77 billion earmarked for reusable‑rocket capacity and RMB 4.73 billion for technology development.
Regulation helped, too. In mid‑2025 China’s securities regulator relaxed Sci‑Tech Board listing criteria and Shanghai Exchange issued a guidance that requires a reusable rocket to have successfully placed a payload into orbit — not necessarily to have completed a recovered first stage. That timing coincided with Blue Arrow’s December orbital milestone and, reportedly, sped its filing and acceptance. More pragmatically, Blue Arrow’s IPO will set a pricing anchor for a cohort of private rocket firms — Tianbing Technology (天兵科技), Xinghe Power (星河动力), Stellar Glory (星际荣耀) and Zhongke Aerospace (中科宇航) among them — all burning cash and racing for secondary‑market capital. The key question remains: are investors pricing a plausible path to scale and recurring revenue, or simply paying for a technology bet with state backing and a favorable policy window? The answer will determine whether RMB 75 billion is foresight — or fever.